year: 2019
pmid: '30659283'
demaria2014:
authors: Demaria M, et al
title: An essential role for senescent cells in optimal wound healing
journal: Dev Cell
year: 2014
pmid: '25481258'
baker2018:
authors: Baker DJ, Petersen RC
title: Cellular senescence in brain aging and neurodegenerative diseases
journal: Lancet Neurol
year: 2018
pmid: '29371448'
copp2008:
authors: Coppé JP, et al
title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions
journal: PLoS Biol
year: 2008
pmid: '19177017'
blagosklonny2013:
authors: Blagosklonny MV
title: Rapamycin treatment of human cells
journal: Cell Cycle
year: 2013
pmid: '24217340'
herranz2015:
authors: Herranz N, et al
title: mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype
journal: Nat Cell Biol
year: 2015
pmid: '26051178'
justice2024:
authors: Justice JN, Nambiar AM, Tchkonia T, et al
title: 'Senolytics: pharmacological interventions for aging'
journal: J Gerontol A Biol Sci Med Sci
year: 2024
hickson2023:
authors: Hickson LJ, Langhi Prata LGP, Bobart SA, et al
title: 'Senolytics decrease senescent cells in humans: a pilot study'
journal: Aging Cell
year: 2023
chaib2022:
authors: Chaib S, Tchkonia T, Kirkland JL
title: 'Cellular senescence and senolytics: the path to translating age-related interventions'
journal: Nat Rev Drug Discov
year: 2022
year: 2019
pmid: '30659283'
demaria2014:
authors: Demaria M, et al
title: An essential role for senescent cells in optimal wound healing
journal: Dev Cell
year: 2014
pmid: '25481258'
baker2018:
authors: Baker DJ, Petersen RC
title: Cellular senescence in brain aging and neurodegenerative diseases
journal: Lancet Neurol
year: 2018
pmid: '29371448'
copp2008:
authors: Coppé JP, et al
title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions
journal: PLoS Biol
year: 2008
pmid: '19177017'
blagosklonny2013:
authors: Blagosklonny MV
title: Rapamycin treatment of human cells
journal: Cell Cycle
year: 2013
pmid: '24217340'
herranz2015:
authors: Herranz N, et al
title: mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype
journal: Nat Cell Biol
year: 2015
pmid: '26051178'
justice2024:
authors: Justice JN, Nambiar AM, Tchkonia T, et al
title: 'Senolytics: pharmacological interventions for aging'
journal: J Gerontol A Biol Sci Med Sci
year: 2024
hickson2023:
authors: Hickson LJ, Langhi Prata LGP, Bobart SA, et al
title: 'Senolytics decrease senescent cells in humans: a pilot study'
journal: Aging Cell
year: 2023
chaib2022:
authors: Chaib S, Tchkonia T, Kirkland JL
title: 'Cellular senescence and senolytics: the path to translating age-related interventions'
journal: Nat Rev Drug Discov
year: 2022
Path: `/mechanisms/senescence-therapeutic-targeting`
Cellular senescence represents a fundamental aging mechanism that contributes to neurodegeneration through both cell-intrinsic dysfunction and the senescence-associated secretory phenotype (SASP)[@kirkland2018]. As senescent cells accumulate in the aging brain, they create a chronic pro-inflammatory microenvironment that drives pathology in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders[@baker2018]. Therapeutic targeting of senescence offers two complementary strategies: senolytic drugs that eliminate senescent cells, and senomorphic agents that suppress the harmful SASP without cell death[@he2017].
This page provides a comprehensive overview of therapeutic approaches to target cellular senescence in neurodegenerative diseases, including mechanistic details, clinical trial status, and intervention points for drug development.
Senolytic drugs selectively induce apoptosis in senescent cells while sparing normal cells. The selective toxicity derives from the heightened dependence of senescent cells on anti-apoptotic pathways—particularly the Bcl-2 family proteins—to survive their pro-inflammatory state[@xu2018].
The combination of dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) represents the most extensively studied senolytic regimen[@kirkland2018]. This combination was identified through high-throughput screening and demonstrated broad senolytic activity across multiple tissue types[@zhu2016].
Dasatinib is an FDA-approved drug for chronic myeloid leukemia that inhibits multiple kinases including Bcr-Abl and Src family kinases. In senescent cells, dasatinib targets Bcl-2, Bcl-xL, and Bcl-w survival proteins, shifting the balance toward [apoptosis](/entities/apoptosis)[@xu2018].
Quercetin is a natural flavonoid with multiple senolytic mechanisms including PI3K/Akt inhibition, Bcl-2 family modulation, and direct effects on multiple pro-survival pathways[@chaib2022]. The combination achieves synergistic senolytic activity with lower doses of each compound than would be required alone.
The D+Q combination has demonstrated preclinical efficacy in neurodegenerative disease models. In tauopathy mice, senolytic treatment reduced senescent glial cells and prevented tau-dependent pathology progression[@bussian2018]. In Alzheimer's disease models, D+Q reduced cognitive decline and neuroinflammation through clearance of senescent microglia[@musi2018].
Navitoclax is a Bcl-2 family inhibitor that targets Bcl-2, Bcl-xL, and Bcl-w[@zhu2016]. Originally developed as an anti-cancer agent, navitoclax demonstrated potent senolytic activity particularly against senescent fibroblasts and [astrocytes](/cell-types/astrocytes).
The mechanism involves:
Navitoclax has shown particular efficacy against senescent [microglia](/cell-types/microglia-neuroinflammation) and neurons in vitro, making it relevant for neurodegenerative applications[@trias2019].
| Agent | Primary Target | Status | CNS Penetration |
|-------|---------------|--------|-----------------|
| ABT-737 | Bcl-2, Bcl-xL, Bcl-w | Preclinical | Limited |
| Fisetin | Multiple | Preclinical | Moderate |
| Piperlongumine | ROS pathways | Preclinical | Unknown |
| 17-DMAG | Hsp90 | Preclinical | Limited |
Senomorphic drugs do not eliminate senescent cells but instead suppress the production and secretion of SASP factors[@he2017]. This approach may offer advantages when complete senescent cell removal could have unintended consequences, such as impairing wound healing or tissue repair[@demaria2014].
The mechanistic target of rapamycin (mTOR) pathway serves as a central regulator of SASP production[@laberge2015]. Rapamycin inhibits mTORC1, which:
Metformin, the widely prescribed type 2 diabetes medication, exhibits senostatic properties through AMPK activation and subsequent mTOR inhibition[@moiseeva2013]. Metformin:
The JAK-STAT pathway plays a critical role in SASP maintenance and autocrine signaling[@xu2015]. JAK inhibitors including ruxolitinib and tofacitinib:
Beyond direct senolytic and senomorphic approaches, additional strategies target specific aspects of SASP biology:
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) serves as the master regulator of SASP transcription. Inhibitors targeting this pathway include:
p38 mitogen-activated protein kinase contributes to SASP regulation through transcription factor C/EBPβ phosphorylation and SASP mRNA stabilization:
The NLRP3 inflammasome represents a key SASP-related target:
| Trial ID | Agent | Phase | Condition | Status |
|----------|-------|-------|-----------|--------|
| NCT02848131 | D+Q | I | COPD/aging | Completed |
| NCT03415087 | D+Q | I | Alzheimer's | Completed |
| NCT04685590 | D+Q | I/II | Parkinson's | Recruiting |
| NCT04833517 | D+Q | II | Cognitive decline | Planning |
The first human senolytic trial (NCT02848131) in idiopathic pulmonary fibrosis demonstrated reduced senescent cell burden in peripheral blood with D+Q treatment[@hickson2023]. A Phase I trial in Alzheimer's disease (NCT03415087) established safety and showed biomarker signals consistent with reduced senescence burden.
Key challenges for clinical translation include:
The senescence-associated secretory phenotype (SASP) includes numerous secreted factors that can serve as biomarkers[@copp2008]:
| Biomarker | Source | Utility |
|-----------|--------|---------|
| IL-6 | Serum | Highest correlation with senescence |
| IL-8 | Serum | SASP marker |
| PAI-1 | Plasma | Senescence-specific |
| CXCL1 | Serum | Pro-inflammatory |
| VEGF | Plasma | Angiogenic SASP |
SA-β-Gal staining: Classic histochemical marker; limited to tissue samples
p16 and p21 markers:
Cellular senescence in AD primarily affects[@ogrodnik2021]:
Senescence in PD involves:
In ALS, senescence affects:
FTD shows senescence in:
| Drug/Compound | Target | Stage | Notes |
|---------------|-------|-------|-------|
| Dasatinib + Quercetin | Bcl-2, PI3K | Phase 1-2 | Most advanced |
| Navitoclax (ABT-263) | Bcl-2/xL/w | Preclinical | Thrombocytopenia |
| Fisetin | Multiple | Preclinical | Natural product |
| ABT-737 | Bcl-2/xL/w | Preclinical | Limited solubility |
| Piperlongumine | ROS pathways | Preclinical | Unclear mechanism |
| 17-DMAG | Hsp90 | Preclinical | Limited CNS penetration |
| Drug/Compound | Target | Stage | Notes |
|---------------|-------|-------|-------|
| Rapamycin | mTOR | Approved (other) | Neuroprotective |
| Metformin | AMPK/mTOR | Approved (DM) | Safety established |
| Ruxolitinib | JAK1/2 | Approved (RA) | Immunosuppression |
| MCC950 | NLRP3 | Preclinical | Potent inflammasome inhibitor |
Senolytic antibodies: Targeting senescent cell surface antigens (uPAR, CD9) for antibody-dependent cellular cytotoxicity
Galactoside-based prodrugs: Activated specifically in senescent cells by elevated β-galactosidase
Gene therapy: Targeted expression of pro-apoptotic genes in senescent cells
Combining senolytic and senostatic approaches may provide synergistic benefits[@kirkland2018]:
Targeting multiple hallmarks of aging:
Off-target effects: Senolytic drugs may affect non-senescent cells, particularly during repeated dosing
Wound healing impairment: Senescent cells play important roles in tissue repair[@demaria2014]
Immune modulation: Chronic senolytic treatment may affect immune surveillance
Thrombocytopenia: Bcl-2 family inhibitors can cause platelet depletion
Monbut invasive |
The senescence-associated secretory phenotype provides accessible biomarkers:
Single-cell approaches reveal cell-type-specific senescence signatures:
Senolytics face unique regulatory challenges:
| Agent | Status | Indication |
|-------|--------|------------|
| Dasatinib | FDA-approved | CML (leukemia) |
| Quercetin | Available as supplement | N/A (not approved) |
| Rapamycin | FDA-approved | Transplant, rare diseases |
| Metformin | FDA-approved | Type 2 diabetes |
Repurposing existing drugs for senolytic indications offers faster development paths.
Future therapies will likely combine:
Understanding cell-type-specific senescenalth and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28593998/)
The following diagram shows the key molecular relationships involving Cellular Senescence Therapeutic Targeting discovered through SciDEX knowledge graph analysis: